HM-15275
- Generic Name
- HM-15275
Hanmi Pharm Accelerates Launch of Efpeglenatide for Obesity Treatment
• Hanmi Pharm aims to launch efpeglenatide, a GLP-1 receptor agonist, for obesity treatment in late 2026, ahead of the previously projected 2027 timeline.
• Efpeglenatide distinguishes itself from other GLP-1 drugs with a gradual release mechanism, potentially reducing gastrointestinal side effects and offering cardiovascular and renal benefits.
• Hanmi is also developing a digital combination drug integrating efpeglenatide with digital therapeutics for personalized obesity management.
• The company's broader Hanmi Obesity Pipeline (H.O.P.) project includes a triple-acting therapy (HM15275) and a novel drug (HM17321) to enhance weight reduction and muscle mass.
Hanmi Pharmaceutical Fast-Tracks Efeglenatide Launch for Obesity Treatment
• Hanmi Pharmaceutical is accelerating the launch of Efeglenatide, an obesity drug, to the second half of 2026, ahead of its initially planned 2027 release.
• Efeglenatide is designed for overweight and stage 1 obesity patients, offering improved gastrointestinal tolerability compared to other GLP-1 treatments.
• The company's Holistic Obesity Program (HOP) includes HM15275, a triple-action obesity treatment, currently in Phase 1 trials in the U.S.
• Hanmi is also developing patient-friendly formulations like oral drugs and micro-needle patches to combat the global obesity epidemic.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath